Published: Aug 21, 2026, 10:31 IST | Updated: Aug 21, 2026, 10:31 IST
Moderna has just delivered a striking example of how medical science can move financial markets. Its shares surged 177 percent in a single session after a personalised mRNA cancer treatment succeeded in a phase 3 trial. But what exactly did investors see, and does every medical breakthrough translate into a stock-market jackpot?